ReShape Lifesciences (RSLS) Competitors

bioAffinity Technologies (NASDAQ:BIAF) and ReShape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Does the media favor BIAF or RSLS?

In the previous week, ReShape Lifesciences had 7 more articles in the media than bioAffinity Technologies. MarketBeat recorded 10 mentions for ReShape Lifesciences and 3 mentions for bioAffinity Technologies. ReShape Lifesciences' average media sentiment score of 0.32 beat bioAffinity Technologies' score of -0.25 indicating that ReShape Lifesciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
ReShape Lifesciences	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, BIAF or RSLS?

bioAffinity Technologies has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Is BIAF or RSLS more profitable?

ReShape Lifesciences has a net margin of -48.26% compared to bioAffinity Technologies' net margin of -110.53%. ReShape Lifesciences' return on equity of -251.90% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-110.53%	-367.64%	-154.15%
ReShape Lifesciences	-48.26%	-251.90%	-59.49%

Do institutionals & insiders hold more shares of BIAF or RSLS?

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are held by institutional investors. 16.9% of bioAffinity Technologies shares are held by company insiders. Comparatively, 0.0% of ReShape Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts prefer BIAF or RSLS?

bioAffinity Technologies presently has a consensus price target of $6.00, suggesting a potential upside of 2,177.04%. Given bioAffinity Technologies' higher possible upside, research analysts clearly believe bioAffinity Technologies is more favorable than ReShape Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ReShape Lifesciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has preferable earnings and valuation, BIAF or RSLS?

ReShape Lifesciences has lower revenue, but higher earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$9.36M	0.80	-$9.04M	-$0.72	-0.37
ReShape Lifesciences	$8.01M	0.73	-$7.13M	-$193.23	-0.01

Summary

ReShape Lifesciences beats bioAffinity Technologies on 8 of the 14 factors compared between the two stocks.